Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Epidermal growth factor receptor inhibition in aerodigestive carcinomas

This week's Journal of the American Medical Association investigates epidermal growth factor receptors as therapeutic targets in aerodigestive carcinomas.

News image

fiogf49gjkf04

Malignancies arising from the aerodigestive epithelium, including lung, head and neck, and esophageal carcinomas, are the leading causes of cancer-related mortality worldwide.

The biological importance of epidermal growth factor receptor in cancer development and progression has been established.

Because of this, epidermal growth factor receptor inhibitors have emerged as promising novel therapies.

Dr Michalis Karamouzis and colleagues from Pennsylvania, USA summarized the current status of epidermal growth factor receptor inhibitors in aerodigestive carcinomas.

The team have highlighted ongoing research designed to optimize their therapeutic effectiveness, and consider the future role of these agents.

The research team performed a systematic MEDLINE search of English-language literature 1966 to 2007.

Multiple epidermal growth factor receptor inhibition strategies are under evaluation
Journal of the American Medical Association

The team used the terms epidermal growth factor receptor, epidermal growth factor receptor inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors.

Search terms including lung cancer, head and neck cancer, esophageal cancer, and epidermal growth factor receptor predictive factors were also used.

Quality assessment of selected studies included clinical pertinence.

To minimize bias, the team considered controlled study design, and publication in peer-reviewed journals.

Adequate number of enrolled patients, objectivity of measurements, and techniques used were also assessed by the researchers.

The team found that the role of the epidermal growth factor receptor in aerodigestive carcinomas pathogenesis has been extensively studied.

The researchers observed that multiple epidermal growth factor receptor inhibition strategies are under evaluation.

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used as a single agent has shown survival benefit in 1 trial of patients with advanced non-small cell lung cancer.

The team noted that cetuximab, an anti- epidermal growth factor receptor monoclonal antibody used in combination with radiation, has also conferred survival benefit in 1 trial of patients with locally advanced head and neck squamous cell carcinoma.

However, other trials have not shown these degrees of improvement.

Epidermal growth factor receptor inhibitors toxicities include rash, diarrhea, and hypomagnesemia.

Somatic mutations and other molecular tumoral characteristics offer opportunities for treatment individualization and optimal patient selection for anti-epidermal growth factor receptor therapy.

Dr Karamouzis' team commented, "Epidermal growth factor receptor is a promising therapeutic target in aerodigestive carcinomas."

"Further translational research is needed to optimize ways of inhibiting epidermal growth factor receptor using single-agent or combination regimens and to identify patients who benefit the most from these therapies."

JAMA 2007: 298(1): 70-82
05 July 2007

Go to top of page Email this page Email this page to a colleague

 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us